AtriCure (NASDAQ: ATRC) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
Earnings & Valuation
This table compares AtriCure and West Pharmaceutical Services’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AtriCure||$155.11 million||3.94||-$33.33 million||($1.02)||-17.38|
|West Pharmaceutical Services||$1.51 billion||4.81||$143.60 million||$2.51||38.94|
This is a breakdown of recent recommendations and price targets for AtriCure and West Pharmaceutical Services, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|West Pharmaceutical Services||0||2||2||0||2.50|
AtriCure currently has a consensus price target of $24.67, suggesting a potential upside of 39.12%. West Pharmaceutical Services has a consensus price target of $106.00, suggesting a potential upside of 8.45%. Given AtriCure’s stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than West Pharmaceutical Services.
This table compares AtriCure and West Pharmaceutical Services’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|West Pharmaceutical Services||12.12%||14.47%||9.71%|
Institutional and Insider Ownership
86.2% of AtriCure shares are owned by institutional investors. Comparatively, 93.3% of West Pharmaceutical Services shares are owned by institutional investors. 11.9% of AtriCure shares are owned by insiders. Comparatively, 1.9% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
AtriCure has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
West Pharmaceutical Services pays an annual dividend of $0.56 per share and has a dividend yield of 0.6%. AtriCure does not pay a dividend. West Pharmaceutical Services pays out 22.3% of its earnings in the form of a dividend. AtriCure has increased its dividend for 25 consecutive years.
West Pharmaceutical Services beats AtriCure on 11 of the 17 factors compared between the two stocks.
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA).
About West Pharmaceutical Services
West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company’s segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.